NCT01131065已完成3 期
Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 4
- 主要终点
- HBV Recurrence
研究概览
简要总结
The aim of this clinical trial is to evaluate the efficacy, safety, and tolerability of Niuliva (Hepatitis B virus immune globulin) in the prophylaxis of hepatitis B virus (HBV) reinfection in patients submitted to liver transplantation due to HBV-induced liver disease by reaching and maintaining certain hepatitis B antibody (HBsAg) levels considered as protective during the first six and twelve months post-transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female.
- •Patients from 18 to 70 years of age (both included).
- •Serum HBV DNA-negative determined by DNA PCR-amplification assay just prior to anhepatic phase visit.
- •Serum HBeAg negative just prior to anhepatic phase visit.
- •Patients who are to undergo liver transplantation due to liver disease associated to HBV.
- •The patient agrees to participate and comply with all the aspects of the protocol, including blood sampling, for the total duration of the study.
- •Signed informed consent.
排除标准
- •Patients who have already experienced a liver transplantation even for reasons not related to HBV infection.
- •Patients with unknown serum HBV replication status (data on HBeAg and HBV DNA).
- •Patients with known allergies to any component of Niuliva®.
- •History of serious adverse events (SAEs) or frequent adverse events (AEs) related to the administration of human blood-derived products.
- •Patient with unknown viral status for HCV, HAV, HIV type 1 and type 2
- •Patients with selective IgA deficiency.
- •Any haemostatic abnormality contraindicating i.v. injection according to the investigator's judgment.
- •Patient suffers from any acute or chronic medical, surgical or psychiatric condition or laboratory abnormality that may increase the risk associated with the study participation or investigational product administration, or may interfere with the interpretation of the study results.
- •Known abuse of alcohol, drugs or other chemical substances; or has done so in the past 6 months.
- •Breast-feeding women or pregnant women at the time of inclusion or who are expecting to be pregnant within the next 7 months after inclusion.
- •Subject has participated in any other investigational study within the last 3 months.
- •Existing possibility that the patient may be treated with other products containing specific anti-hepatitis B immunoglobins (other than Niuliva®) in a period of 13 months.
- •Subject is incapable of giving consent personally.
研究组 & 干预措施
Hepatitis B immune globulin
Experimental
Treatment group (newly liver transplanted subjects due to HBV induced liver disease)
干预措施: Hepatitis B immune globulin (Drug)
结局指标
主要结局
HBV Recurrence
时间窗: First six and twelve months after liver transplantation
HBV recurrence is measured by seroconversion or reappearance of HBsAg and HBV DNA positivity
HBsAb Pre-infusion Levels (Trough Levels Before Each Niuliva Administration)
时间窗: Days 3 to 7, Weeks 2 to 4, Months 2 to 6, and Months 7 to 12
次要结局
- Safety and Tolerance(During and after each product administration (during the 12 month treatment period))
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19Omicron Variant of COVID-19NCT05813600Xiangao Jiang58
已完成
不适用
Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab TherapyMelanomaNCT02990611Bristol-Myers Squibb1,087
已完成
3 期
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma PatientsMesotheliomaNCT02899299Bristol-Myers Squibb605
已完成
不适用
Clinical trials for efficacy and safety for a novel device intermediating traditional needle electrodes to BIS-VISTA system for frontal neurosurgical procedureGeneral Anesthesia cases management with processed EEG monitoringJPRN-UMIN000031217Kurume University20
招募中
不适用
A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)Acute Ischemic StrokeNCT06070753Shaare Zedek Medical Center30